Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients

被引：9

作者：

Powell, BL

Bydder, S

Grieu, F

Gnanasampanthan, G

Elsaleh, H

Seshadri, R

Berns, EMJJ

Iacopetta, B ^{[1
]}

机构：

[1] Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia

[2] Sir Charles Gairdiner Hosp, Dept Radiat Oncol, Nedlands, WA, Australia

[3] Flinders Univ S Australia, Flinders Med Ctr, Dept Hematol & Oncol, Bedford Pk, SA, Australia

[4] Univ Hosp Rotterdam DDHK, Dept Med Oncol, Div Endocrine Oncol, Rotterdam, Netherlands

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 01期

关键词：

adjuvant therapy; breast carcinoma; chemotherapy; hormonal therapy; prognostic marker; predictive marker; TP53;

D O I：

10.1023/A:1012233509663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated the prognostic significance of mutation to the TP53 tumor suppressor gene in a series of 908 breast cancer patients treated with or without adjuvant therapies. The frequency of TP53 mutation detected by single strand conformation polymorphism (SSCP) was 19.4% (176/908) in the overall tumor series. In multivariate analysis, TP53 mutation was independently associated with worse survival in the overall (HR = 2.1, 95% CI [1.5-3.1], P < 0.0001), non-adjuvant treated (HR = 2.2, 95% CI [1.2-4.2], P = 0.017) and adjuvant treated (HR = 2.0, 95% CI [1.3-3.1], P = 0.0009) patients.

引用

页码：65 / 68

页数：4

共 25 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].

BERGH, J ;

NORBERG, T ;

SJOGREN, S ;

LINDGREN, A ;

HOLMBERG, L .

NATURE MEDICINE, 1995, 1 (10) :1029-1034

[3]

Berns EMJJ, 2000, CANCER RES, V60, P2155

[4]

Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO

[5]

2-G

[6]

Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO

[7]

2-8

[8]

Chevillard S, 1997, CLIN CANCER RES, V3, P2471

[9]

Clarke M, 1998, LANCET, V351, P1451

[10] P53 MUTATIONS AND OVEREXPRESSION IN LOCALLY ADVANCED BREAST CANCERS [J].

FAILLE, A ;

DECREMOUX, P ;

EXTRA, JM ;

LINARES, G ;

ESPIE, M ;

BOURSTYN, E ;

DEROCQUANCOURT, A ;

GIACCHETTI, S ;

MARTY, M ;

CALVO, F .

BRITISH JOURNAL OF CANCER, 1994, 69 (06) :1145-1150

← 1 2 3 →